Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magrico is a combination pharmaceutical product developed and marketed by Lyf Healthcare, primarily indicated for the management of muscle cramps, magnesium deficiency, and neuromuscular health. It consists of magnesium bisglycinate, a highly bioavailable chelated form of magnesium, and L-carnitine L-tartrate. Magnesium acts as a critical cofactor for numerous enzymatic reactions and serves as a physiological calcium antagonist, helping to regulate muscle contraction and nerve conduction. L-carnitine facilitates the transport of long-chain fatty acids into the mitochondria for beta-oxidation and energy production, which is essential for maintaining muscle function and reducing fatigue. The combination is frequently utilized for nocturnal leg cramps, pregnancy-induced cramps, and supportive care in neuropathic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium bisglycinate + levocarnitine tartrate.